Profil
Brian Sun is currently the Senior Vice President & General Counsel at Turning Point Therapeutics, Inc. Prior to this, he worked as the Secretary, Senior VP & General Counsel at Sorrento Therapeutics, Inc. He holds a graduate degree from The Johns Hopkins University, an undergraduate degree from the University of California, Berkeley, and a graduate degree from the University of San Diego.
Aktive Positionen von Brian Sun
| Unternehmen | Position | Beginn |
|---|---|---|
| TURG POIN | General Counsel | 11.04.2022 |
Ehemalige bekannte Positionen von Brian Sun
| Unternehmen | Position | Ende |
|---|---|---|
| SORRENTO THERAPEUTICS, INC. | General Counsel | - |
Ausbildung von Brian Sun
| University of San Diego | Graduate Degree |
| The Johns Hopkins University | Graduate Degree |
| University of California, Berkeley | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| SORRENTO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Turning Point Therapeutics, Inc.
 Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
